March 2024, Vol 5, No 1

Richard Kim, MD, presented the results of a phase 2, open-label study of patients who underwent telotristat ethyl plus first-line chemotherapy for the treatment of advanced biliary tract cancer.

Junji Furuse, MD, PhD, presented the results of a phase 2 study of tasurgratinib efficacy on patients with FGFR2 fusion-positive cholangiocarcinoma following gene fusion status confirmation by fluorescence in situ hybridization.

Teresa Macarulla, MD, PhD, presented the results of 2 phase 1a/1b dose-escalation/expansion trials, studies that measured the efficacy and safety of brigimadlin in patients with advanced biliary tract cancer.

To encourage participation, especially among minority groups, CCA News provides Twenty-Five ongoing US-based clinical trials to improve cholangiocarcinoma treatment outcomes.

The Cholangiocarcinoma Foundation (CCF) will host the 11th Annual CCF Conference in Salt Lake City, Utah, from April 17 to 19. This article summarizes the conference’s itinerary, overarching goals, and participating speakers.

A recombinant bispecific antibody, CTX-009, is discussed regarding its role in an ongoing phase 2/3 open-label, randomized, controlled study—a study being conducted to measure the efficacy of CTX-009 in previously treated, advanced, or metastatic biliary tract cancer.

Cholangiocarcinoma experts presented the preliminary results of a phase 2 clinical trial regarding anlotinib plus TQB2450, nab-paclitaxel, and cisplatin—a study conducted for the treatment of advanced biliary tract cancer.

Zongli Zhang, MD, PhD, presented the preliminary results of an ongoing single-arm, multicenter, open-label, real-world study analyzing the efficacy and safety of surufatinib as a second-line treatment option for patients with biliary tract cancer.

Riya Jayesh Patel, MD, presented how the impact of transcriptomic signatures related to chemotherapy and immunotherapy sensitivity in the cholangiocarcinoma (CCA) cohort of The Cancer Genome Atlas could serve as evidence supporting the effectiveness of metabolism-targeted therapies in overcoming CCA therapeutic resistance.